Maintenance With Selinexor/Placebo After Combination Chemotherapy in Participants With Endometrial Cancer [SIENDO]
Public ClinicalTrials.gov record NCT03555422. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, Phase 3 Trial of Maintenance With Selinexor/ Placebo After Combination Chemotherapy for Patients With Advanced or Recurrent Endometrial Cancer
Study identification
- NCT ID
- NCT03555422
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Karyopharm Therapeutics Inc
- Industry
- Enrollment
- 263 participants
Conditions and interventions
Conditions
Interventions
- Matching placebo for selinexor Drug
- Selinexor Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 4, 2018
- Primary completion
- Jan 21, 2022
- Completion
- Apr 2, 2025
- Last update posted
- Apr 12, 2026
2018 – 2025
United States locations
- U.S. sites
- 19
- U.S. states
- 13
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Arizona Oncology | Tucson | Arizona | 85711 | — |
| Stanford University | Palo Alto | California | 94304 | — |
| Moffitt Cancer Center | Tampa | Florida | 33612 | — |
| Florida Cancer Specialists (Sarah Cannon Research Institute) | West Palm Beach | Florida | 33401 | — |
| Gynecological Cancer Institute of Chicago | Oak Lawn | Illinois | 60453 | — |
| Parkview Research Center | Fort Wayne | Indiana | 46845 | — |
| Indiana University Simon Cancer Center | Indianapolis | Indiana | 46202 | — |
| HCA Midwest Health - Kansas City (Sarah Cannon Research Institute) | Kansas City | Missouri | 64132 | — |
| NYU Langone | New York | New York | 10016 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | — |
| University of Oklahoma Health Sciences Center - Stephenson Cancer Center | Oklahoma City | Oklahoma | 73104 | — |
| Oncology Associates of Oregon | Eugene | Oregon | 97401 | — |
| Women & Infants Hospital of Rhode Island | Providence | Rhode Island | 02905 | — |
| Tennessee Oncology Nashville (Sarah Cannon Research Institute) | Nashville | Tennessee | 37203 | — |
| Texas Oncology, Austin | Austin | Texas | 78731 | — |
| Texas Oncology DFW | Dallas | Texas | 75246 | — |
| University of Texas Southwestern Medical Center | Dallas | Texas | 75390 | — |
| Texas Oncology DFW | Fort Worth | Texas | 76104 | — |
| VCU Massey Cancer Center | Richmond | Virginia | 23298 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 59 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03555422, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 12, 2026 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03555422 live on ClinicalTrials.gov.